Chengxiang Shan

Prof. Chengxiang Shan


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HLHaili Lu
Haili Lu
SZSiluo Zha
Siluo Zha
WZWei Zhang
Wei Zhang
QWQiang Wang
Qiang Wang
DJDaozhen Jiang
Daozhen Jiang
CSChengxiang Shan
Chengxiang Shan
Background: Although various clinical trials and real-life studies have tried to explore the value of nab-paclitaxel mono-chemotherapy for metastatic breast cancer (MBC), the safety and efficacy of nab-paclitaxel remain unclear which need to be systematically evaluated. Methods: Electronic searches for prospective clinical trials evaluating nab-paclitaxel monotherapy for MBC were performed. Requisite data were extracted, integrated and analysed from the included studies according to the different study designs using systematic review and meta-analysis. Meta-regression and subgroup analysis were further performed to explore the potential risk factors affecting each individual outcome of interest following nab-paclitaxel monotherapy. Results: Twenty-two studies with 3287 MBC patients were included. A total of 1685 MBC patients received nab-paclitaxel as first-line therapy, 640 patients as further-line therapy, and 962 patients as mixed-line therapy. A total of 1966 MBC patients (60.40%) received nab-paclitaxel weekly, 1190 patients (36.56%) received nab-paclitaxel triweekly and 99 patients (3.04%) received nab-paclitaxel biweekly. The overall incidence rates of all-grade neutropenia, leukopenia, peripheral sensory neuropathy, and fatigue were 52% (95% CI, 38–66%, I2 = 98.97%), 58% (95% CI, 43–73%, I2 = 97.72%), 58% (95% CI, 48–68%, I2 = 97.17%), and 49% (95% CI, 41–56%, I2 = 94.39%), respectively. The overall response rate (ORR) was 40% (95% CI, 35–45%, I2 = 98.97%), and the clinical benefit rate (CBR) was 66% (95% CI, 59–73%, I2 = 98.97%) following nab-paclitaxel monotherapy. The median progression-free survival (PFS) was 7.64 months (95% CI, 6.89–8.40 months, I2 = 92.3%), and the median overall survival (OS) was 24.51 months (95% CI, 21.25–27.78 months, I2 = 92.7%). Treatment line, human epidermal growth factor receptor-2(Her-2)-negative status and dosage were found to be sources of heterogeneity among the included studies. According to the meta-regression and subgroup analysis, grade 3/4 neutropenia occurred less frequently in Her-2-negative patients than in the entire population (P = 0.046). Patients who received first-line nab-paclitaxel monotherapy showed a higher ORR (P = 0.006) and longer PFS (P = 0.045). Efficacy outcomes were not affected by the administration schedule. However, within the same schedule, patients appeared to have a superior ORR (P = 0.044) and longer PFS (P = 0.03) with an increasing dosage of nab-paclitaxel administered. Conclusions: The benefits brought by nab-paclitaxel mono-chemotherapy in the treatment of MBC are considerable while the harm is generally manageable. Further study and validation are needed to figure out the roles which the dosage, schedule and other factors play actually in nab-paclitaxel chemotherapy.

1 December 2021 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
XWXiang Wei
Xiang Wei
LCLiang Chen
Liang Chen
AYAiming Yang
Aiming Yang
ZLZhaoyu Lv
Zhaoyu Lv
MXMeng Xiong
Meng Xiong
CSChengxiang Shan
Chengxiang Shan
ADRB2 is a potential protective gene in breast cancer by regulating tumor immune microenvironment Xiang Wei, Liang Chen, Aiming Yang, Zhaoyu Lv, Meng Xiong, Chengxiang Shan

20 July 2020 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
RHRenhong Huang
Renhong Huang
QWQiang Wang
Qiang Wang
WZWei Zhang
Wei Zhang
SZSiluo Zha
Siluo Zha
DJDaozhen Jiang
Daozhen Jiang
CSChengxiang Shan
Chengxiang Shan

29 April 2020 in The American Journal of Surgery
Verified
Journal Article
Closed access
PDF file
WLWei Li
Wei Li
BLBingyang Liu
Bingyang Liu
CSChengxiang Shan
Chengxiang Shan
ZLZhiyong Liu
Zhiyong Liu
QWQiang Wang
Qiang Wang
MQMing Qiu
Ming Qiu

2 December 2022 in Frontiers in Endocrinology
Verified
Journal Article
Open access
LLLei Li
Lei Li
QSQixuan Sheng
Qixuan Sheng
HZHuajin Zeng
Huajin Zeng
WLWei Li
Wei Li
QWQiang Wang
Qiang Wang
CSChengxiang Shan
Chengxiang Shan
Background: Hypothyroidism is a common hormone deficiency disorder. Although hormone supplemental therapy can be easily performed by daily levothyroxine administration, a proportion of patients suffer from persisting complaints due to unbalanced hormone levels, leaving room for new therapeutic strategies, such as tissue engineering and regenerative medicine.Methods: Electronic searches of databases for studies of thyroid regeneration or thyroid organoids were performed. A systematic review including both in vitro and in vivo models of thyroid regenerative medicine was conducted.Results: Sixty-six independent studies published between 1959 and May 1st, 2022 were included in the current systematic review. Among these 66 studies, the most commonly involved species was human (19 studies), followed by mouse (18 studies), swine (14 studies), rat (13 studies), calf/bovine (4 studies), sheep/lamb (4 studies) and chick (1 study). In addition, in these experiments, the most frequently utilized tissue source was adult thyroid tissue (46 studies), followed by embryonic stem cells (ESCs)/pluripotent stem cells (iPSCs) (10 studies), rat thyroid cell lines (7 studies), embryonic thyroid tissue (2 studies) and newborn or fetal thyroid tissue (2 studies). Sixty-three studies reported relevant thyroid follicular regeneration experiments in vitro, while 21 studies showed an in vivo experiment section that included transplanting engineered thyroid tissue into recipients. Together, 12 studies were carried out using 2D structures, while 50 studies constructed 3D structures.Conclusions: Each aspect of thyroid regenerative medicine was comprehensively described in this review. The recovery of optimal hormonal equilibrium by the transplantation of an engineered functional thyroid holds great therapeutic promise.

11 March 2025 in Annals of Medicine
Verified
Journal Article
Open access
QSQixuan Sheng
Qixuan Sheng
WLWei Li
Wei Li
PZPing Zhang
Ping Zhang
QWQiang Wang
Qiang Wang
SZSiluo Zha
Siluo Zha
CSChengxiang Shan
Chengxiang Shan
To assess the impact of parathyroid gland (PG) classification on hypoparathyroidism incidence following total thyroidectomy (TT) with central neck dissection (CND) in patients with differentiated thyroid carcinoma (DTC). In this prospective cohort study, adult patients with DTC who underwent TT with CND between 2021 and 2023 were enrolled, with a maximum follow-up duration of 32 months. A simplified PG classification system was employed, categorizing glands into four distinct types: tightly connected, loosely connected, non-connected, and thymic. The intraoperative frequency of each PG type was recorded based on this classification. Parathyroid hormone (PTH) levels were routinely tested 1 day, 1 month, 6 months and 1 year after surgery. The association between PG classification and the incidence of postoperative hypoparathyroidism was then systematically analysed. Among 135 patients with DTC (mean age: 48.50 ± 10.52 years; 101 women), 62 patients (45.93%) developed hypoparathyroidism on postoperative day 1 (POD1), while 14 patients (10.37%) experienced hypoparathyroidism on postoperative month 1 (POM1). All patients exhibited PTH normalization within six months, with no permanent hypoparathyroidism cases. A total of 532 PGs were identified: 264 (49.62%) were tightly connected, 150 (28.20%) loosely connected, 95 (17.86%) non-connected, and 23 (4.32%) thymic. The highest prevalence of hypoparathyroidism on POD1 was observed in patients with four tightly connected PGs (p < 0.001). Patients with four tightly connected PGs had a significantly greater incidence of hypoparathyroidism than those with none (p = 0.024). Regression analysis revealed that each additional tightly connected PG increased the risk of hypoparathyroidism by 1.38 times (p = 0.019). Tightly connected PGs demonstrated predictive value for POD1 hypoparathyroidism (AUC = 0.604, cut-off: two tightly connected glands). In contrast, thymic PGs did not provide a protective effect. PG classification may serve as a valuable tool for surgeons in intraoperative parathyroid preservation and the prediction of postoperative hypoparathyroidism in patients with DTC. Notably, DTC patients with more than two tightly connected PGs are at an elevated risk of developing temporary hypoparathyroidism, emphasizing the importance of meticulous parathyroid preservation during surgical procedures.